Skip to main content

Lower Mortality Results from Lower Activity in Lupus

Data from the longitudinal Tromsø Lupus Cohort study has shown that lupus patients who achieve a Lupus Low Disease Activity State (LLDAS‐50) were shown to have significantly less severe damage, and a reduction in mortality.

This was a population‐based study of SLE patients in the northern‐most counties of Norway.

They collected data on the LLDAS; defined as:

  1. SLEDAI‐2K ≤4, with no activity in major organ systems
  2. no new features of lupus disease activity
  3. current prednisolone (or equivalent) dose ≤7.5 mg daily, and,
  4. well tolerated standard maintenance doses of immunosuppressive drugs.

They followed a total of 206 SLE patients 84% female) with a median follow up of 125 months. Overall there were 46 (22%)  deaths.

Prednisolone (89%) and hydroxychloroquine (59%) were the most common drugs used and only 3.4% required cyclophosphamide or rituximab. A positive anti-nuclear antibody (ANA+) was evident in nearly all (96%).

LLDAS (any duration) was achieved by 74% of the cohort. The median time in LLDAS was 34 months and 69 patients (33.5%) spent at least half of their time in LLDAS. 

Lower mortality rates and a lower risk of severe damage was seen in the 69 patients (33.5%) who spent at least half of their follow up time in LLDAS.

The LLDAS‐50 was associated with a significantly lower in risk of having severe damage (HR 0.37; 95%CI 0.19 – 0.73, p < 0.01), and also a reduction in mortality (HR 0.31; 95%CI 0.16 – 0.62, p < 0.01).

Treat to target and measure of low activity can have a powerful effect on lupus outcomes. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject